Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Research and development	$ 8,309	$ 1,800	$ 21,615	$ 6,632
General and administrative	3,062	2,135	9,374	4,537
Total operating expenses	11,371	3,935	30,989	11,169
Loss from operations	(11,371)	(3,935)	(30,989)	(11,169)
Other income (expense)
Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability				(81,157)
Interest income, net	663	14	1,000	22
Other income, net	(2)	19	(1)	47
Total other income (expense)	661	33	999	(81,088)
Net loss	(10,710)	(3,902)	(29,990)	(92,257)
Other comprehensive loss
Unrealized loss on marketable securities		(28)	(734)	(28)
Comprehensive loss	$ (10,710)	$ (3,930)	$ (30,724)	$ (92,285)
Net loss per common share, basic	$ (0.26)	$ (0.1)	$ (0.74)	$ (7)
Net loss per common share, diluted	$ (0.26)	$ (0.1)	$ (0.74)	$ (7)
Weighted-average shares outstanding, basic	40,502,860	38,266,593	40,491,181	13,177,983
Weighted-average shares outstanding, diluted	40,502,860	38,266,593	40,491,181	13,177,983